Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
We devised a sensitive, radioimmunoprecipitation assay (RIPA) for anti-interferon (IFN)-beta-binding antibody (BAB) detection. Our RIPA showed good agreement with a reference RIPA (mean difference, -3.2 +/- 10.6 AU), and detected BAB to both IFN-beta-1a and IFN-beta-1b. Neutralizing antibodies to IF...
Κύριοι συγγραφείς: | Lampasona, V, Rio, J, Franciotta, D, Furlan, R, Avolio, C, Fazio, R, Lavolpe, V, Vincent, A, Comi, G, Trojano, M, Montalban, X, Martino, G |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
2003
|
Παρόμοια τεκμήρια
-
Drug induced liver injury secondary to interferon-beta (IFN-β) in multiple sclerosis
ανά: V. Byrnes, κ.ά.
Έκδοση: (2006-01-01) -
The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
ανά: Damiano Paolicelli, κ.ά.
Έκδοση: (2016-01-01) -
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
ανά: Damiano Paolicelli, κ.ά.
Έκδοση: (2009-07-01) -
Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta.
ανά: Marta F Bustamante, κ.ά.
Έκδοση: (2013-01-01) -
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
ανά: Lisa G M van Baarsen, κ.ά.
Έκδοση: (2008-04-01)